Arrowpoint Investment Partners Singapore Pte. Ltd. Invests $1.19 Million in Regeneron Pharmaceuticals, Inc. $REGN

Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, Holdings Channel reports. The firm bought 1,538 shares of the biopharmaceutical company’s stock, valued at approximately $1,187,000.

Other large investors have also bought and sold shares of the company. WPG Advisers LLC increased its position in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $31,000. Entrust Financial LLC purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $32,000. Torren Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $38,000. Finally, FNY Investment Advisers LLC purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $38,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

REGN has been the subject of several recent research reports. TD Cowen lifted their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Citigroup cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $900.00 to $700.00 in a research report on Monday, May 18th. Leerink Partners reiterated a “market perform” rating and issued a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $800.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $792.65.

Regeneron Pharmaceuticals Trading Up 1.6%

Shares of REGN stock opened at $628.73 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a market capitalization of $66.47 billion, a PE ratio of 15.32, a price-to-earnings-growth ratio of 1.37 and a beta of 0.25. The business’s fifty day moving average is $709.21 and its 200 day moving average is $742.91.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s revenue was up 19.0% compared to the same quarter last year. During the same quarter last year, the business posted $8.22 earnings per share. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its strategic cancer partnership with CytomX to develop conditionally activated bispecific therapeutics, adding two new programs and optionality for more targets, which strengthens the company’s oncology pipeline and long-term growth prospects. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: Regeneron also said it will highlight new clinical data and research from its metabolic disease, ophthalmology, and rare disease pipelines at upcoming ADA and ENDO meetings, reinforcing investor focus on multiple potential catalysts beyond oncology. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Analyst and market commentary pointed to the expanded oncology collaboration and positive clinical trial updates as the reasons REGN shares moved higher, suggesting sentiment is being driven by pipeline optionality and business-development momentum. Why Regeneron (REGN) Stock Is Trading Up Today
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of Regeneron investors, which could create headline risk, though the notice did not include any findings or financial impact. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.